天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Doxorubicin hydrochloride
  • Doxorubicin hydrochloride

多柔比星,Doxorubicin hydrochloride,25316-40-9

價(jià)格 276 1158
包裝 5mg 50mg
最小起訂量 5mg
發(fā)貨地 上海
更新日期 2024-08-30

產(chǎn)品詳情

英文名稱:Doxorubicin hydrochlorideCAS:25316-40-9
品牌: 愛必信(absin)產(chǎn)地: 上海
保存條件: Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.純度規(guī)格: >98%
產(chǎn)品類別: 生化試劑 小分子化合物
2024-08-30 Doxorubicin hydrochloride Doxorubicin hydrochloride 5mg/276RMB;50mg/1158RMB 276 愛必信(absin) 上海 Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. >98% 生化試劑 小分子化合物
描述

Doxorubicin (Adriamycin) is an antibiotic agent that inhibits DNA topoisomerase II and induces DNA damage and apoptosis.

純度
>98%
儲(chǔ)存/保存方法
Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.
基本信息
別名
多柔比星;NSC 123127;Adriamycin; Hydroxydaunorubicin hydrochloride;
外觀
Powder
可溶性/溶解性
DMSO:100 mg/mL warmed (172.41 mM)

Water:20 mg/mL (34.48 mM)
生物活性
靶點(diǎn)
Topo II
In vitro(體外研究)
Doxorubicin, an antibiotic anthracycline, is commonly considered to exert its anti-tumor activity at two fundamental levels, altering DNA and producing free radicals to trigger apoptosis of cancer cells through DNA damage. Doxorubicin can block the synthesis of DNA by intercalating into the DNA strand, and inhibits DNA topoisomerase II (TOP2). Doxorubicin is most effective when cells are rapidly proliferating and expressing high levels of TOP2. Additionally, Doxorubicin can trigger apoptosis by producing ceramide (which prompts apoptosis by activating p53 or other downstream pathways such as JNK), the degradation of Akt by serine threonine proteases, the mitochondrial release of cytochrome c, increased FasL (death receptor Fas/CD95 ligand) mRNA production, and a greater production of free radicals. Pre-treatment with GSNO (nitrosoglutathione) suppresses the resistance in the doxorubicin-resistant breast cancer cell line MCF7/Dx, accompanied by enhanced protein glutathionylation and accumulation of doxorubicin in the nucleus. Doxorubicin induced G2/M checkpoint arrest are attributed to elevated cyclin G2 (CycG2) expression and phospho-modification of proteins in the ataxia telangiectasia mutated (ATM) and ATM and Rad3-related (ATR) signaling pathways. Doxorubicin inhibits AMP-activated protein kinase (AMPK), resulting in SIRT1 dysfunction, p53 accumulation, and increased cell death in mouse embryonic fibroblasts (MEFs) and cardiomyocytes, which can be further sensitized by pre-inhibition of AMPK. Doxorubicin elicits a marked heat shock response, and that either inhibition or silencing of heat shock proteins enhance the Doxorubicin apoptotic effect in neuroblastoma cells. Nanomolar Doxorubicin treatment of neuroblastoma cells causes dose-dependent over-ubiquitination of a specific set of proteins in the absence of measurable inhibition of proteasome, and loss of activity of ubiquitinated enzymes such as lactate dehydrogenase and α-enolase, the protein ubiquination patterns of which is similar to those with proteasome inhibitor Bortezomib, indicating that Doxorubicin may also exert its effect by damaging proteins.
In vivo(體內(nèi)研究)
In vivo, Doxorubicin in combination with adenoviral MnSOD (AdMnSOD) plus 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) has the greatest effect in decreasing the volumes of MB231 tumors and prolonging survival of mice. Although its use is limited by the chronic and acute toxic side effects it produces, Doxorubicin is essential in treating breast and oesophageal carcinomas, solid tumours in childhood, osteosarcomas, Kaposi's sarcoma, soft tissue sarcomas, and Hodgkin and non-Hodgkin lymphomas.
參考文獻(xiàn)
參考文獻(xiàn)
[1] Sun W, et al. Cancer Res, 2009, 69(10), 4294-4300.
[2]Granados-Principal S, et al. Food Chem Toxicol, 2010, 48(6), 1425-1438.
[3] de Luca A, et al. Biochem J, 2011, 440(2), 175-183.
[4] Cheriyath V, et al. Br J Cancer, 2011, 104(6), 957-967.
[5] Zimmermann M, et al. J Biol Chem, 2012, 287(27), 22838-22853.
[6] Wang S, et al. J Biol Chem, 2012, 287(11), 8001-8012.
[7] Luke JJ, et al. Clin Cancer Res, 2012, 18(9), 2638-2647.
[8] Mandili G, et al. FEBS J, 2012, 279(12), 2182-2191.

分子結(jié)構(gòu)圖


關(guān)鍵字: 多柔比星;25316-40-9;abs810716;

公司簡(jiǎn)介

愛必信(上海)生物科技有限公司成立于2010年,位于上海市申江科創(chuàng)園。是一家自主研發(fā)和生產(chǎn)生物試劑的公司。 Absin?是愛必信(上海)生物科技有限公司的試劑品牌,目前已近60萬種生化試劑,10萬種抗體,其基礎(chǔ)生化試劑在基礎(chǔ)科學(xué)領(lǐng)域得到廣泛應(yīng)用的同時(shí),特色產(chǎn)品線常規(guī)生化試劑,血清,小分子激動(dòng)劑及抑制劑在業(yè)界也備受好評(píng)。 Absin秉承踏實(shí),務(wù)實(shí),求精和不斷創(chuàng)新的精神為中國科學(xué)家提供最好的產(chǎn)品,努力打造屬于中國自己的生物試劑品牌,為廣大科學(xué)家提供更全面更豐富更優(yōu)質(zhì)的產(chǎn)品。 愛科研,必信它(Absin)!Absin努力成為你身邊的科研百寶箱!
成立日期 2010-12-13 (15年) 注冊(cè)資本 2500萬
員工人數(shù) 100-500人 年?duì)I業(yè)額 ¥ 1000萬-5000萬
主營(yíng)行業(yè) 生化試劑,抗體,分子生物學(xué),生物活性小分子 經(jīng)營(yíng)模式 工廠
  • 愛必信(上海)生物科技有限公司
非會(huì)員
  • 公司成立:15年
  • 注冊(cè)資本:2500萬
  • 企業(yè)類型:有限責(zé)任公司
  • 主營(yíng)產(chǎn)品:二抗、標(biāo)簽抗體、對(duì)照抗體;WB相關(guān):ECL發(fā)光液、預(yù)染marker、預(yù)制膠;IHC相關(guān):二抗試劑盒、組化筆;IP/CoIP試劑盒;細(xì)胞因子、信號(hào)通路調(diào)節(jié)劑;血清、BSA、蛋白酶K、CTB、TTX、CEE;凋亡試劑盒、呼吸爆發(fā)試劑盒;動(dòng)植物提取物,定制服務(wù)(抗體/多肽/蛋白)...
  • 公司地址:上海市浦東新區(qū)新浩路58號(hào)18號(hào)樓
詢盤

多柔比星,Doxorubicin hydrochloride,25316-40-9相關(guān)廠家報(bào)價(jià)

更多
產(chǎn)品名稱 價(jià)格   公司名稱 報(bào)價(jià)日期
¥280
VIP6年
濟(jì)寧心和化工有限公司
2025-01-09
¥650
VIP12年
湖北威德利化學(xué)科技有限公司
2025-01-09
詢價(jià)
VIP2年
武漢鼎程生科化學(xué)試劑有限公司
2025-01-09
詢價(jià)
VIP6年
武漢榮燦生物科技有限公司
2025-01-09
詢價(jià)
VIP6年
湖北威德利化學(xué)試劑有限公司
2025-01-09
詢價(jià)
VIP4年
河北陌槿生物科技有限公司
2025-01-09
詢價(jià)
VIP5年
武漢華玖醫(yī)藥科技有限公司
2025-01-09
¥400.00
VIP9年
北京索萊寶科技有限公司
2025-01-09
詢價(jià)
VIP12年
深圳振強(qiáng)生物技術(shù)有限公司
2025-01-09
詢價(jià)
VIP6年
武漢鼎信通藥業(yè)有限公司
2025-01-09
內(nèi)容聲明:
以上所展示的信息由商家自行提供,內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由發(fā)布商家負(fù)責(zé)。 商家發(fā)布價(jià)格指該商品的參考價(jià)格,并非原價(jià),該價(jià)格可能隨著市場(chǎng)變化,或是由于您購買數(shù)量不同或所選規(guī)格不同而發(fā)生變化。最終成交價(jià)格,請(qǐng)咨詢商家,以實(shí)際成交價(jià)格為準(zhǔn)。請(qǐng)意識(shí)到互聯(lián)網(wǎng)交易中的風(fēng)險(xiǎn)是客觀存在的